MedTrace Logo

Trial of PTK787/ZK 222584 Plus Paclitaxel

NCT00358163 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-04-29

No results posted yet for this study

Summary

PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of the impact of PTK787/ZK 222584 on paclitaxel metabolism and evaluation of tumor response to the investigational treatment.

Conditions

  • Metastatic Non-hematologic Malignancies

Interventions

DRUG

PTK787/ZK 222584

Taken in tablet form daily

DRUG

paclitaxel

Given as a 3-hour infusion once every 21 days

Sponsors & Collaborators

Principal Investigators

  • Pankaj Bhargava, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-26
Primary Completion
2008-05-29
Completion
2008-05-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358163 on ClinicalTrials.gov